Redeye provides an update following Guldbrev’s Q3 report, which showed continued progress but missed Redeye’s expectations. Redeye reduces its near-term estimates while still expecting healthy figures in the coming quarters in absolute terms. $GULD redeye.se/research/1188118/g…

Redeye comments on Binero Group’s Q3 trading update, which supports Redeye’s current full-year forecast and valuation. redeye.se/research/1188102/b… $BINERO

Redeye has interviewed Hexatronic’s CEO Rikard Fröberg, who talks about the third quarter, including the decision to reverse the downsizing of the Clinton factory, the demand situation in Harsh Environment, and the accelerating growth in Data Center. Fröberg also comments on the bottlenecks for some input materials and talks about what is next for Hexatronic. $HTRO redeye.se/research/1188274/h…

Redeye provides an update on Litium’s Q3 report, which showed the strongest quarter in its history. $LITI redeye.se/research/1188294/l…

Redeye comments on Freemelt receiving another major order to manufacture tungsten components, this time from the European Spallation Source (ESS). $FREEM redeye.se/research/1188301/f…

Maven Wireless trades below Redeye's Fair Value estimate of SEK 5.2 per share and has Market Edge scores of 3 for Value (Fairly Priced) and 3 for Momentum (Neutral). We spoke with our analyst about what the company does and who its customers are, the trade-off between focus and growth in Maven's new strategy, and other key topics. This is a premium article, included in our paid plans from SEK 99/month. $MAVEN redeye.se/research/1188193/m…

Redeye comments on Dynavox’s Q3 report, which was slightly softer than expected. Sales missed by 2% as Medicaid-related reimbursement friction held back US growth, while the EBIT beat was flattered by a SEK16m earn-out reversal. $DYVOX redeye.se/research/1188148/d…

Redeye has interviewed Physitrack’s CEO Henrik Molin about the Q3 2026 report, where revenue grew 14% and the core Physitrack platform grew 26%. Henrik also discusses when he expects margins to return to the 40-45% target and what the two US healthcare system wins mean. $PTRK redeye.se/research/1188215/p…

Redeye provides an update following Vertiseit’s Q3 report. $VERT redeye.se/research/1187211/v…

Redeye comments on q.beyond's preliminary Q3 2026 figures and second guidance cut in three months. $QBY redeye.se/research/1188135/q…

Redeye has interviewed Litium's CEO, Martin Billenius, who shares insights on the Q3 report, momentum in the current sales pipeline and what reaching profitability means going into 2027. $LITI redeye.se/research/1188096/l…

Redeye har intervjuat Carasents VD Daniel Öhman, som berättar om det senaste kvartalet samt den goda utvecklingen i det nyligen förvärvade Infosolutions. Vidare beskriver Öhman AI-produkten Medsum, vad den ger kunderna och hur planerna för vidareutveckling ser ut. Därtill resonerar Öhman kring AI och SaaS generellt givet senaste tidens utveckling. Slutligen berättar Öhman om situationen i Tyskland. $CARA redeye.se/research/1188095/c…

Top Picks is back with an update, making a single move: a full exit from one position where the case we underwrote has not developed as expected. Instead of staying anchored to a drifting thesis, we would rather take the capital home and hold it as dry powder, keeping the option to revisit the name with fresh eyes. Top Picks is included in our premium memberships from SEK 349/month. redeye.se/research/1188091/t…

Redeye updates on EG7 ahead of Q3-results (due 10 November). $EG7 redeye.se/research/1188052/e…

Redeye provides an update following Physitrack’s Q3 report. $PTRK redeye.se/research/1187969/p…

Redeye provides an update following I-Tech’s Q3 report. $ITECH redeye.se/research/1187990/q…

Redeye provides an update following Lime’s Q3 report, lowering its Base Case to SEK339 (354) as a higher risk-free rate in its WACC offsets 3% higher EBITDA-CAPEX estimates after the Q3 beat. Redeye still sees a solid case with high predictability. $LIME redeye.se/research/1187186/l…

Redeye presents its preview for Senzime’s Q3 2026 report, due on October 29. $SEZI redeye.se/research/1187963/s…

Björn Borg trades below Redeye's Fair Value estimate of SEK 73.6 per share and has Market Edge scores of 4 for Value (Attractively Priced) and 3 for Momentum (Neutral). We spoke with our analyst about Björn Borg's business model and main sales channels, the competitive advantage in sports apparel, and other key topics. This is a premium article, included in our paid plans from SEK 99/month. $BORG redeye.se/research/1187906/b…